<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01914562</url>
  </required_header>
  <id_info>
    <org_study_id>747-104</org_study_id>
    <nct_id>NCT01914562</nct_id>
  </id_info>
  <brief_title>Effect of Food on Pharmacokinetics of Obeticholic Acid (OCA)</brief_title>
  <official_title>An Open Label Trial to Assess the Effects of Food on the Pharmacokinetic Parameters of Obeticholic Acid (OCA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intercept Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intercept Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, randomized, balanced, single center, single dose, trial to assess the&#xD;
      pharmacokinetic (PK) profile of OCA, glyco-OCA and tauro-OCA on an empty stomach (fasted&#xD;
      condition) and following a high fat, high calorie meal (fed condition) in a 2-period,&#xD;
      2-sequence, crossover manner.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum concentration (Cmax) - fed and fasted</measure>
    <time_frame>Day 1 and Day 14: 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, and 14 hours</time_frame>
    <description>maximum concentration (observed)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum concentration (Tmax)</measure>
    <time_frame>24 hours</time_frame>
    <description>Time to maximum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration versus time (AUCt)</measure>
    <time_frame>216 hours</time_frame>
    <description>Area under the concentration versus time curve from time 0 to the last sampling time with measurable analyte concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration versus time curve from 0 to 24 hours (AUC 0-24)</measure>
    <time_frame>24 hours</time_frame>
    <description>Area under the concentration versus time curve from 0 to 24 hours with measurable analyte concentration</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>OCA 10 mg while fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OCA 10 mg orally in the fasting state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OCA 10 mg while Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OCA 10 mg orally in the fed state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OCA 25 mg while fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OCA 25 mg orally in the fasting state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OCA 25 mg while Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OCA 25 mg orally in the fed state</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OCA 10 mg</intervention_name>
    <description>OCA 10 mg tablet oral</description>
    <arm_group_label>OCA 10 mg while Fed</arm_group_label>
    <arm_group_label>OCA 10 mg while fasted</arm_group_label>
    <other_name>6α-ethyl chenodeoxycholic acid;(6-ECDCA), INT-747</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OCA 25 mg</intervention_name>
    <description>OCA 25 mg tablet oral</description>
    <arm_group_label>OCA 25 mg while Fed</arm_group_label>
    <arm_group_label>OCA 25 mg while fasted</arm_group_label>
    <other_name>6α-ethyl chenodeoxycholic acid;(6-ECDCA), INT-747</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects are required to meet the following criteria in order to be included in the trial.&#xD;
&#xD;
          1. Male or female subjects from 18 to 55 years&#xD;
&#xD;
          2. Contraception: Female subjects must be postmenopausal, surgically sterile, or if&#xD;
             premenopausal, be prepared to use more than 1 effective (≤ 1% failure rate) method of&#xD;
             contraception during the trial and until at least 30 days after the last dose of OCA.&#xD;
             Effective methods of contraception are considered to be:&#xD;
&#xD;
               1. Double barrier method, ie, (a) condom (male or female) with spermicide or (b)&#xD;
                  diaphragm with spermicide&#xD;
&#xD;
               2. Intrauterine device (IUD)&#xD;
&#xD;
               3. Vasectomy&#xD;
&#xD;
          3. Good general health as determined by medical history, and by results of physical&#xD;
             examination, vital signs, electrocardiogram (ECG), and clinical laboratory tests&#xD;
             obtained within 14 days prior to Day 0&#xD;
&#xD;
          4. Body mass index (BMI) of 18 to 28; BMI is determined by the following equation: BMI =&#xD;
             weight/height2 (kg/m2).&#xD;
&#xD;
          5. Willing to abstain from alcohol, caffeine, and xanthine-containing food and beverages&#xD;
             for 72 hours prior to each period check in and during participation of the inpatient&#xD;
             periods of the trial&#xD;
&#xD;
          6. Willing and able to give written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects meeting the following criteria will be excluded from the trial.&#xD;
&#xD;
          1. Prior participation in a clinical trial of OCA (INT-747; 6-ECDCA)&#xD;
&#xD;
          2. History or presence of any disease or condition known to interfere with the&#xD;
             absorption, distribution, metabolism, or excretion of drugs including bile salt&#xD;
             metabolism in the large intestine, eg, inflammatory bowel disease&#xD;
&#xD;
          3. History of gastrointestinal surgeries or gall bladder removal (cholecystectomy)&#xD;
&#xD;
          4. History or presence of a clinically significant cardiovascular, hepatic, diabetic,&#xD;
             gastrointestinal, metabolic, neurologic, pulmonary, endocrine, psychiatric, or&#xD;
             neoplastic disorder(s)&#xD;
&#xD;
          5. History of known or suspected clinically significant hypersensitivity to any drug,&#xD;
             aside from penicillin&#xD;
&#xD;
          6. Ingestion of a prescription medication within 14 days prior to Day 0 or ingestion of&#xD;
             an over the counter medication within 7 days prior to Day 0&#xD;
&#xD;
          7. Participation in radiologic examinations involving parenteral administration of&#xD;
             iodinated contrast materials within 2 weeks prior to screening, or subsequently,&#xD;
             through the end of trial participation&#xD;
&#xD;
          8. History or presence of alcohol abuse (defined as consumption of more than 210 mL of&#xD;
             alcohol per week; or the equivalent of fourteen 4 ounces (oz) glasses of wine, or&#xD;
             fourteen 12 oz cans/bottles of beer or wine coolers per week)&#xD;
&#xD;
          9. History or presence of substance abuse within the past 2 years or positive drug screen&#xD;
             tests&#xD;
&#xD;
         10. Smoker or user of tobacco or nicotine products&#xD;
&#xD;
         11. Any screening laboratory test for which the results are not within the normal&#xD;
             reference range and considered clinically significant&#xD;
&#xD;
         12. Participation in another investigational drug trial within 30 days prior to Day 0&#xD;
&#xD;
         13. History of noncompliance to medical regimens, or subjects who are considered to be&#xD;
             potentially unreliable&#xD;
&#xD;
         14. Blood or plasma donation within 30 days prior to Day 0&#xD;
&#xD;
         15. Mental instability or incompetence&#xD;
&#xD;
         16. Presence of human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B&#xD;
             virus (HBV) at screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Shapiro, MD</last_name>
    <role>Study Director</role>
    <affiliation>Intercept Pharmaceticals, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Terry E. O'Reilly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Celrion, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion, Inc.</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>July 31, 2013</study_first_submitted>
  <study_first_submitted_qc>July 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2013</study_first_posted>
  <last_update_submitted>August 7, 2014</last_update_submitted>
  <last_update_submitted_qc>August 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chenodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

